Keyword Analysis & Research: impel neuropharma

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
impel neuropharma0.80.978228117
impel1.880.89370915
neuropharma1.370.789034511

Keyword Research: People who searched impel neuropharma also searched

Keyword CPC PCC Volume Score
impel neuropharma1.010.2458394
impel neuropharma stock1.310.5390767
impel neuropharma inc impl1.240.71677100
impel neuropharma news1.910.2728754
impel neuropharma ipo1.460.172099
impel neuropharma email0.70.9166679
impel neuropharma cafepharma0.211305817
impel neuropharma market cap0.360.3472523
impel neuropharma press release1.070.3727326
impel neuropharma stock investing1.790.750920
impel neuropharma inc0.240.1472538

Search Results related to impel neuropharma on Search Engine

  • Home | Impel Pharmaceuticals

    impelpharma.com

    https://impelpharma.com/

    WebImpel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimer's, migraine, and other central nervous system diseases.

    DA: 38 PA: 6 MOZ Rank: 13

  • Impel Neuropharma Announces Company Will Now Be Known as …

    globenewswire.com

    https://www.globenewswire.com/news-release/2022/04/25/2427959/0/en/Impel-Neuropharma-Announces-Company-Will-Now-Be-Known-as-Impel-Pharmaceuticals-to-Reflect-Corporate-Transformation.html

    WebSEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...

    DA: 25 PA: 72 MOZ Rank: 47

  • Impel NeuroPharma Announces Launch of Proposed Public Offering

    impelpharma.com

    https://impelpharma.com/2021/09/07/impel-neuropharma-announces-launch-of-proposed-public-offering/

    WebSEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that it has commenced an underwritten public ...

    DA: 100 PA: 96 MOZ Rank: 86

  • Impel Neuropharma Announces Company Will Now Be Known as Impel

    yahoo.com

    https://finance.yahoo.com/news/impel-neuropharma-announces-company-now-110000724.html

    WebSEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...

    DA: 86 PA: 16 MOZ Rank: 57

  • IMPEL NEUROPHARMA ANNOUNCES FDA SUBMISSION OF ... - Impel …

    impelpharma.com

    https://impelpharma.com/2020/11/09/impel-neuropharma-announces-fda-submission-of-new-drug-application-for-inp104-for-the-acute-treatment-of-migraine/

    WebSEATTLE, November 9, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) for INP104 (dihydroergotamine mesylate) or DHE to the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine headaches with or without aura in adult patients.

    DA: 68 PA: 20 MOZ Rank: 25

  • Impel NeuroPharma enters migraine market with FDA nod for …

    reuters.com

    https://www.reuters.com/world/us/us-fda-approves-impel-neuropharmas-acute-migraine-treatment-2021-09-03/

    WebSept 3 (Reuters) - Impel NeuroPharma Inc's (IMPL.O) nasal spray to treat migraine got approval from the U.S. health regulator on Friday, marking the company's entry into a crowded market of...

    DA: 37 PA: 26 MOZ Rank: 78

  • Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA

    yahoo.com

    https://finance.yahoo.com/news/impel-neuropharma-announces-u-fda-125000945.html

    WebSEATTLE, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...

    DA: 63 PA: 93 MOZ Rank: 40

  • Impel NeuroPharma Announces Fourth Quarter and Full Year

    globenewswire.com

    https://www.globenewswire.com/news-release/2022/03/24/2409365/0/en/Impel-NeuroPharma-Announces-Fourth-Quarter-and-Full-Year-2021-Financial-Results-and-Provides-Corporate-Update.html

    WebSEATTLE, March 24, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...

    DA: 52 PA: 44 MOZ Rank: 47

  • Impel NeuroPharma Announces Fourth Quarter and Full Year …

    yahoo.com

    https://finance.yahoo.com/news/impel-neuropharma-announces-fourth-quarter-120000912.html

    WebMar 24, 2022 · Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update. March 24, 2022 · 16 min read. Impel NeuroPharma. Trudhesa™ Exceeds Fourth...

    DA: 34 PA: 98 MOZ Rank: 19

  • Impel NeuroPharma, fresh off IPO, gets FDA approval for ... - GeekWire

    geekwire.com

    https://www.geekwire.com/2021/impel-neuropharma-fresh-off-ipo-gets-fda-approval-nasal-spray-treats-migraines/

    WebSep 3, 2021 · The U.S. Food and Drug Administration has approved Impel NeuroPharma’s Trudhesa to treat migraine headaches, the Seattle company announced Friday. Trudhesa leverages Impel’s upper nasal...

    DA: 47 PA: 14 MOZ Rank: 39